scholarly article | Q13442814 |
P50 | author | Juan Pasquau | Q56863306 |
Samantha Elizabeth de Jesus | Q59702693 | ||
Alberto Romero Palacios | Q81565702 | ||
P2093 | author name string | Arkaitz Imaz | |
José Hernández-Quero | |||
María Carmen Fariñas | |||
Fernando Lozano | |||
Koldo Aguirrebengoa | |||
Pilar Vázquez | |||
Juan Flores | |||
María José Galindo | |||
Isabel Sanjoaquín | |||
Jorge Vergas | |||
Carmen Hidalgo-Tenorio | |||
Ignacio de Los Santos | |||
María Luisa Montes | |||
María José Ríos-Villegas | |||
Francisco Orihuela | |||
Coral García-Vallecillos | |||
Isabel García-Mercé | |||
QoLKAMON STUDY GROUP | |||
P2860 | cites work | Simplification of antiretroviral therapy: a good choice for our patients and the sustainability of our health care system. | Q45974592 |
Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. | Q46059384 | ||
Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppression. | Q46460347 | ||
Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale | Q46572937 | ||
The level of persistent HIV viremia does not increase after successful simplification of maintenance therapy to lopinavir/ritonavir alone | Q58000879 | ||
Análisis farmacoeconómico de una estrategia de mantenimiento con lopinavir/ritonavir como monoterapia en pacientes con infección por el VIH | Q58000881 | ||
Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice | Q80446898 | ||
[Validation of a questionnaire to estimate satisfaction with antiretroviral treatment: CESTA questionnaire] | Q81567538 | ||
Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 PI-based regimen | Q28741214 | ||
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. | Q34289633 | ||
Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature | Q34535751 | ||
Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa | Q34734833 | ||
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment | Q35193958 | ||
Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial | Q36613143 | ||
Boosted protease inhibitor monotherapy in HIV-infected adults: outputs from a pan-European expert panel meeting | Q36722728 | ||
Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. | Q37052827 | ||
Molecular basis of human immunodeficiency virus drug resistance: an update. | Q37555266 | ||
Boosted protease inhibitor monotherapy. What have we learnt after seven years of research? | Q37788957 | ||
Protease inhibitor monotherapy. | Q37819920 | ||
Iatrogenic mitochondriopathies: a recent lesson from nucleoside/nucleotide reverse transcriptase inhibitors. | Q37991644 | ||
Protease inhibitor monotherapy as maintenance regimen in patients with HIV infection | Q38046883 | ||
Responsiveness of the MOS-HIV and EQ-5D in HIV-infected adults receiving antiretroviral therapies | Q38089967 | ||
Central nervous system HIV infection in "less-drug regimen" antiretroviral therapy simplification strategies | Q38203208 | ||
Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial | Q38499842 | ||
Assessment of second-line antiretroviral regimens for HIV therapy in Africa | Q38861912 | ||
A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. | Q40082978 | ||
Effect of lopinavir/ritonavir monotherapy on quality of life and self-reported symptoms among antiretroviral-naive patients: results of the MONARK trial. | Q42663879 | ||
Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy | Q43102710 | ||
Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial | Q43124622 | ||
Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study). | Q43172783 | ||
Changes in quality of life among persons with HIV infection | Q43409011 | ||
Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study | Q43901817 | ||
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. | Q44043469 | ||
Budget impact analysis of switching to darunavir/ritonavir monotherapy for HIV-infected people in Spain | Q44583194 | ||
Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine | Q44710862 | ||
[Lopinavir/ritonavir monotherapy as a simplification strategy in antiretroviral therapy in clinical practice]. | Q45942565 | ||
[Lopinavir/ritonavir monotherapy. Possible indications]. | Q45942567 | ||
[Lopinavir/ritonavir monotherapy as a simplification strategy in the treatment of HIV-1 infection]. | Q45942570 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | lopinavir | Q422585 |
ritonavir | Q422618 | ||
lopinavir/ritonavir | Q3836750 | ||
P304 | page(s) | e0195068 | |
P577 | publication date | 2018-04-12 | |
P1433 | published in | PLOS One | Q564954 |
P1476 | title | High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trial | |
P478 | volume | 13 |
Q58122670 | Comparison of Zidovudine and Tenofovir Based Regimens With Regard to Health-Related Quality of Life and Prevalence of Symptoms in HIV Patients in a Kenyan Referral Hospital |
Q95641549 | Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial |
Q90675802 | HPV-associated anal lesions in HIV+ patients: long-term results regarding quality of life |
Search more.